720,000 Shares in Teva Pharmaceutical Industries Limited (NYSE:TEVA) Purchased by NWI Management LP

NWI Management LP acquired a new position in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 720,000 shares of the company's stock, valued at approximately $15,869,000. Teva Pharmaceutical Industries comprises about 0.7% of NWI Management LP's holdings, making the stock its 20th largest holding. NWI Management LP owned about 0.06% of Teva Pharmaceutical Industries at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of TEVA. Barclays PLC raised its holdings in Teva Pharmaceutical Industries by 31.7% in the 3rd quarter. Barclays PLC now owns 427,595 shares of the company's stock valued at $7,705,000 after acquiring an additional 102,848 shares during the last quarter. Franklin Resources Inc. boosted its stake in Teva Pharmaceutical Industries by 141.7% during the third quarter. Franklin Resources Inc. now owns 155,091 shares of the company's stock worth $2,674,000 after buying an additional 90,920 shares during the last quarter. Park Avenue Securities LLC grew its holdings in Teva Pharmaceutical Industries by 23.2% in the 4th quarter. Park Avenue Securities LLC now owns 12,434 shares of the company's stock valued at $274,000 after buying an additional 2,341 shares in the last quarter. Redhawk Wealth Advisors Inc. acquired a new stake in shares of Teva Pharmaceutical Industries in the 4th quarter worth $1,155,000. Finally, Contravisory Investment Management Inc. acquired a new position in shares of Teva Pharmaceutical Industries during the 4th quarter valued at about $221,000. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

TEVA has been the subject of several analyst reports. StockNews.com upgraded Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research report on Wednesday, April 23rd. Barclays cut their price objective on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating for the company in a research report on Thursday, January 30th. JPMorgan Chase & Co. raised shares of Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and upped their target price for the company from $21.00 to $23.00 in a research report on Monday. Bank of America lifted their price target on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a "buy" rating in a research report on Thursday, May 8th. Finally, UBS Group lowered their price objective on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a research report on Thursday, January 30th. Eight equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $24.43.

Teva Pharmaceutical Industries Trading Down 2.7%

TEVA opened at $17.48 on Wednesday. The business has a fifty day moving average price of $15.22 and a 200 day moving average price of $17.44. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75. Teva Pharmaceutical Industries Limited has a 12 month low of $12.47 and a 12 month high of $22.80. The stock has a market capitalization of $19.82 billion, a price-to-earnings ratio of -12.06, a PEG ratio of 1.44 and a beta of 0.62.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.05. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. The firm had revenue of $3.89 billion for the quarter, compared to analysts' expectations of $3.99 billion. During the same quarter last year, the company earned $0.48 earnings per share. The firm's revenue was up 1.9% compared to the same quarter last year. Sell-side analysts expect that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.